News
-
-
-
-
-
-
PRESS RELEASE
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz reaches agreement with Regeneron on patent litigation related to US aflibercept biosimilar, enabling launch of Enzeevu™ by end of 2026. Agreement strengthens Sandoz biosimilar portfolio and expands US market growth strategy -
-
REGULATED PRESS RELEASE
Half-year report 2025
-
REGULATED PRESS RELEASE
Solid results in H1 2025. Operating margin: 23.2% - Net margin: 16.4%
Interparfums reports solid financial results in H1 2025 with an operating margin of 23.2% and a net margin of 16.4%. Sales reached €447m, a 5.8% increase compared to H1 2024. Key acquisitions and strategic plans ahead -